USCOM LIMITED — AGM Information 2023

Oct 25, 2023

==> picture [140 x 35] intentionally omitted <==

FY23 AGM Presentation and Update ASX: UCM

• MedTech in active growth phase

• Products and markets

• Partnerships

• Rebound ready

• Prepared for strategic restructure

Prof. Rob Phillips Chairman and CEO, Uscom Limited

Oct 26, 2023

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Uscom Vision

“A great company, with great vision, technology and culture, and a great global commercial opportunity”

A Company for the Future

Clinical Mission - To save lives each day in clinical conditions responsible for over 75% of human mortality by demonstrating world leadership in science and creating premium non-invasive cardiovascular pulmonary devices

Commercial Mission – To generate sustainable organic and innovative incremental growth to create an enterprise of scale, profitability and influence.

Global operations across 6 Australia China Hungary Singapore UK

~2,000 > 160 IP Over 20 years Sales into 52 >1,000 peer Installed submissions in business countries publications USCOM 1A IP submissions $27m sales over 10 Global clinical International peer USCOM 1A units protecting Uscom years adoption across reviewed US installed globally technology many applications publications

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Uscom Value

Advanced Global Medtech Company

Great company, vision, technology, culture and global opportunity Expanding international sales Established global operations

Flagship Technologies

Flagship technologies in prestige cardiovascular and pulmonary sector.

10 year CAGR growth trend

2000 units into 52 countries Sales >$27m AUD over 10 years Total Receipts FY23 $3.30m AUD) Debt free with cash on hand $2.18m AUD Growth drivers poised

Impending value drivers

Foxconn partnership, new products, US distribution, new China and US regulatory approvals, European distribution, SE Asia distribution, China “MIC 25” compliant.

06 01

==> picture [89 x 145] intentionally omitted <==

----- Start of picture text -----

02
----- End of picture text -----

Strategic Restructure

05

Singapore based acquisition and logistical focus to attract capital and drive organic and incremental global growth.

==> picture [258 x 116] intentionally omitted <==

----- Start of picture text -----

04 03
----- End of picture text -----

Deep IP and academic recognition

200+ IP submissions

Multiple Uscom devices and technology, ~1000 Peer reviewed papers.

Uscom - The Measure of Life

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

==> picture [4 x 4] intentionally omitted <==

Uscom Medical Technology

Future growth from expanding products and global operations

World leading medical technology (ASX:UCM) with global footprint – Sydney, Singapore, Beijing, Budapest, London Delaware

• Cardiovascular and pulmonary devices

• Expanding product portfolio

• Digital technology

• Wireless connectivity

Flagship science and technology in prestige CVP sector. Multiple products with global regulatory, Addressing diseases responsible for >75% of all mortality

~1000 publications and multiple global practice guidelines

~2000 USCOM 1A sales into 52 countries

$27m Sales over 10 years

Foxconn manufacturing partnership to underwrite growth Chinese Foxconn domestic manufacturing, in global operations High margin and ~160 IP protected devices

==> picture [140 x 140] intentionally omitted <==

==> picture [109 x 72] intentionally omitted <==

==> picture [119 x 84] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [97 x 109] intentionally omitted <==

==> picture [45 x 86] intentionally omitted <==

==> picture [83 x 59] intentionally omitted <==

==> picture [145 x 109] intentionally omitted <==

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

FY23 Results

Returning to growth

UCM Total Receipts Trend FY12 – FY24*

==> picture [318 x 249] intentionally omitted <==

==> picture [48 x 47] intentionally omitted <==

==> picture [48 x 49] intentionally omitted <==

$2.18 million

$3.30 million

Cash on Hand

Total Receipts

Building the future

Results

Sale of Goods $2.66m up 6% from $2.51m in pcp Total Annual Revenue $3.15mil, down 3% on pcp Strong second half growth:

H2 > H1 up 51%, and Q4 > Q3 up 162%

Cash on Hand = $2.18m, down from $4.70m in FY22

==> picture [39 x 39] intentionally omitted <==

==> picture [43 x 16] intentionally omitted <==

----- Start of picture text -----

51%
----- End of picture text -----

H2 > H1

Growth trendline impacted by H1 pandemic, Russian war, recession fears, local manufacture in China, trade wars and geopolitical tensions in FY22 and FY23 Anticipated growth trend to continue in FY24, based on record Q4 and historical records suggest a restoration to previous revenues as the rebound continues.

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au FY21 Results

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

FY23 Results – H2

A tale of two halves

==> picture [290 x 258] intentionally omitted <==

----- Start of picture text -----

UCM FY2023 Results H1 v H2
2 1.9
1.84
1.8
1.64
1.6
1.46
1.4
1.26
1.2
1.02
1 H1
H2
0.8
0.6
0.4
0.2
0
$m
----- End of picture text -----

Sales Revenue Total Revenue Cash Receipts

==> picture [48 x 47] intentionally omitted <==

==> picture [49 x 48] intentionally omitted <==

==> picture [39 x 39] intentionally omitted <==

$2.18 million $1.19 million $1.84 million Cash on Hand Q4 sales H2 receipts

==> picture [503 x 32] intentionally omitted <==

----- Start of picture text -----

Sales Impact -30% +61% +50%
----- End of picture text -----

Timeframe	H1 FY23	H2 FY23	H1 FY24
Challenges #1	COVID lockdown	Opened	-
Challenges #2	Domestic Manufacture in China	Pending	Approved
Challenges #3	Inflation and high interest rates	Moderating	Reduced
Challenges #4	Russian war	Adapted	Chronic
Challenges #5	International Geopolitics	Challenging	Uncertain

+61% +51% +26%

Uscom - The Measure of Life

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au FY21 Results

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

FY23 Results – Q4

Quarter and Half Growth

==> picture [265 x 24] intentionally omitted <==

----- Start of picture text -----

UCM Q4 Sales FY12 – FY23
----- End of picture text -----

==> picture [284 x 272] intentionally omitted <==

==> picture [48 x 48] intentionally omitted <==

==> picture [48 x 48] intentionally omitted <==

==> picture [39 x 38] intentionally omitted <==

$2.18 million $1.19 million

$1.84 million

Cash on Hand

Q4 sales H2 receipts

Building the future

Results – Quarter and Half

• H2 revenue up 51% from H1

• Q4 total income up 51% from pcp

• Q4 total income up 104% from Q3

• Cash on Hand = $2.18m (after $0.62m for EABB)

• Early signs of rebound

Strong Q4, growth trend expected to continue to rebound in FY24.

Growth drivers in FY2024:

• Domestic manufacture

• Foxconn partnership

• Open international economies post COVID zero policies

Uscom - The Measure of Life

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

FY23 Results - by Region

Uscom Total Revenue by Region – FY 2023

Uscom Total Revenue by Region

==> picture [294 x 212] intentionally omitted <==

----- Start of picture text -----

28%
34%
Asia
Europe
US/Other
Australia
2%
36%
----- End of picture text -----

• Global platform for growth

• Hedged for currency and shifting geopolitics

Asia - $0.90 million

Sales reduced 34% due to COVID Zero and domestic manufacturing regulations, China remains Uscom’s largest market and with the Foxconn solution now complete and new distributors being appointed revenue is showing strong early growth signs.

US/Other - $0.04 million

The US remains a difficult and unpredictable market with budget constraints and internal administrative disruption effecting consumer confidence and health spending.

Europe - $0.97 million

Sales were increased despite the Russian war and COVID tail in response to the restructure in Uscom Europe showing profit in the second half.

Australia - $0.76 million

The Australian ROW market showed a small rebound as specialist international markets inceased.

• Global reporting, tax, transfer pricing and auditing

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Products and Markets

High value technologies - large markets - strong predicted growth 3 high value product divisions – cardiac, hypertension/vascular and pulmonary

$21.6B USD 5yr CAGR 4.8%

==> picture [227 x 171] intentionally omitted <==

$1.4B USD 8yr CAGR 11.2%

==> picture [275 x 171] intentionally omitted <==

$1.3B USD 5yr CAGR 8.16%

==> picture [256 x 138] intentionally omitted <==

USCOM 1A

The Global Cardiac Monitoring & Cardiac Rhythm Management Market is estimated to increase from $21.6B HSD in 2020 to $27.31B USD by 2025, at a CAGR of 4.8%.

Heart failure, Sepsis, Fluid management, COVID

BP+

The global BP monitoring devices market is $1.4B USD and is expected to reach $5.1B USD by 2030 at a CAGR of 11.2%.

Hypertension, Vascular health

SpiroSonic AIR

The global spirometer market is expected to grow rom $1.269B USD in 2019 to $2.198B USD in 2026 at a CAGR of 8.16%.

Asthma, COPD, OLD, COVID

Uscom – Devices the Experts Use

Note: Researchandmarkets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au FY21 Results

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

SpiroSonic AIR

Next generation spirometry

“Hospital in Home” – Asthma, COVID, COPD and Occupational Lung disease Applications - Research/CRO, hospital, clinic, and eHealth home management The SpiroSonic AIR Cycle – Digital data, information, diagnosis and reports generating a cascade of revenue

eHealth Revenue Cascade

• Device sale

• APP Sale

• Software sale

• Cloud storage - Big data

• AI analysis

• Clinician diagnosis

• Prescription

• Report

• System subscription

==> picture [134 x 90] intentionally omitted <==

==> picture [233 x 232] intentionally omitted <==

Digital Home Care Asthma Solution

Home care solution, digital ultrasonic AIR spirometer, BT4 digital connectivity, AIR App and software, Connected to cloud or SpiroReporter.

Revolutionising management of asthma, COPD and COVID

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

International Brands and eHealth

5 great International Brands across 3 product divisions

==> picture [93 x 76] intentionally omitted <==

Blue Sky Uscom eHealth Ecosystem

Global Medtech Revenues in 2019 ~$500B USD Global Medtech Growth in 2019 5.5% Global Medtech R&D in 2019 ~$31B USD

https://www.statista.com/topics/1702/medical-technology-industry/#dossierContents__outerWrapper

eHealth market expected to grow from USD $59.60 billion in 2020 to USD $206.30 billion in 2027.

% 19.4

eHealth Market forecast to grow at CAGR of 19.4% for the next 7 years

Uscom - The Measure of Life

Uscom Group International Brands

	International Brand Branding Sector
	Uscom is an emerging global leader in non- invasive cardiovascular and pulmonary medical devices, developing innovative technologies to solve the challenges of global disease and health care. Cardiovascular Pulmonary
	USCOM 1A Non-invasive hemodynamic monitor. USCOM 1A uses advanced Doppler hemodynamics to monitor cardiac blood flow. Cardiovascular
	Supra-systolic oscillometric central blood pressure monitor BP & Vascular
	Reporter The Uscom BP+ Reporter is a patient archiving, analysis and reporting software for use with the Uscom BP+. BP & Vascular
	SpiroSonic digital ultrasonic spirometers provide ultrasonic spirometry solutions for clinicians and patients. Pulmonary
	SpiroReporter spirometry software solution that provides real-time diagnostics, archiving, analysis, trend analysis, configurable reports, export Pulmonary
	VentiTest is an innovative multi-path digital ultrasonic ventilator calibration solution Pulmonary
	Blue Sky Uscom eHealth Ecosystem world leading digital technologies into the new cloud based Uscom eHealth Ecosystem E-health

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Global Approvals

Regulatory approvals proceeding

==> picture [579 x 293] intentionally omitted <==

==> picture [333 x 286] intentionally omitted <==

----- Start of picture text -----

Regulatory Approvals
China SE Asia Euro US Russia ROW
23/24 USCOM 1A
New New 23/24 BP+
✓ ✓
23/24 New 23/24 SpiroSonic
✓ ✓
2023 2 2023+
----- End of picture text -----

==> picture [86 x 57] intentionally omitted <==

==> picture [39 x 28] intentionally omitted <==

Regulatory approvals – expensive and unpredictable Increasingly valuable – key to revenue

==> picture [72 x 30] intentionally omitted <==

==> picture [73 x 43] intentionally omitted <==

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

IP Value

Global Assets

Revenue protection

Next Generation Products

==> picture [525 x 31] intentionally omitted <==

----- Start of picture text -----

Registered IP Uscom Ltd Uscom China Uscom Kft Total
----- End of picture text -----

USCOM 1A	115	33	-	148
BP+	10	-	-	10
SpiroSonic	1	-	1	2
VentiTest	-	-	1	1
Total	126	33	2	161

==> picture [75 x 69] intentionally omitted <==

==> picture [68 x 66] intentionally omitted <==

==> picture [55 x 60] intentionally omitted <==

==> picture [62 x 61] intentionally omitted <==

==> picture [88 x 58] intentionally omitted <==

==> picture [141 x 28] intentionally omitted <==

==> picture [300 x 351] intentionally omitted <==

New Ideas – New Products – New value

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Publications – Clinical value

Uscom - leader in world cardiovascular and pulmonary science

==> picture [84 x 123] intentionally omitted <==

==> picture [77 x 114] intentionally omitted <==

==> picture [72 x 99] intentionally omitted <==

==> picture [76 x 103] intentionally omitted <==

==> picture [69 x 98] intentionally omitted <==

==> picture [69 x 96] intentionally omitted <==

==> picture [60 x 95] intentionally omitted <==

==> picture [66 x 96] intentionally omitted <==

==> picture [71 x 95] intentionally omitted <==

==> picture [78 x 117] intentionally omitted <==

==> picture [76 x 120] intentionally omitted <==

==> picture [79 x 115] intentionally omitted <==

>1,000

Peer reviewed publications

3

Global Guidelines

Applications

Emergency, Pediatrics, Cardiac transplantation, Hypertension, Electrophysiology, Heart Failure, Emergency transport, Anesthesia, Liver transplantation, ICU, Septic shock, Preeclampsia, Pulmonary hypertension, Exercise physiology, Nurse outreach, Organ procurement, Cancer, Haemodialysis, Neonates, infants, Children adults, elderly etc……..

“Saving lives worldwide”

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Uscom Devices in World’s Best Hospitals

==> picture [896 x 416] intentionally omitted <==

----- Start of picture text -----

Europe – Slovenjia – Lubiana Asia - China -
University Medical Center Europe - Poland –Lodz Chongqing
PERIN Chongqing Asia - China – Beijing
US – Chicago Europe - Italy – Roma Polish Mother’s Memorial Hospital Chilren’s Hospital Fuwai Cardiovascular Hospital
Illinois Children’s
Policlinico Casilino
Hospital Hospital Europe - Chekz Asia - China – Jinan
Europe - Italy – Padova
Rep – Praga Shandong Provincial Hospital
Policlinico - TIN Charles University
US – Pittsburgh Asia - China -
Europe - Italy – Milano
UPMC Children’s IRCCS Policlinico – Europe - Hungary – Chengdu Asia - China – Asia - China – Shanghai
Hospital Pittsburgh Clinica Mangiagalli Budapest West China Shenzhen Children’s Hospital of Shanghai
US – Cincinnatti Szent Istvan & Szenr Women’s and
Cincinnatti Children’s US – Houston Europe - Italy – Milano Laszlo Hospital Children’s Hospital Children’s HospitalShenzhen
HospitaL Texas Children’s Policlinico – Clinica De Asia - China – Shanghai
Hospital Marchi - PS Europe - Switzerland - Geneva FuDan Univeristy HuaShan Hospital
Hopiteaux Universitaire de
Geneve
Europe - Italy – Parma & Firenze Asia - China – Fujian
A.O.U. Parma & A.O.U. Careggi – Europe - Austria – Vienna Fijian Maternal and Children’s Hospital
US – LA US – St Louis Materno Infantile Medical University Asia - China -Guangzhou
Children’s Hospital of Barnes Jewish Hospital Europe - Italy – Trieste Guandong
Europe - Italy – Faenza
Los Angeles Ospedale Burlo Garofolo General Hospital Asia - China – Xiamen
Ospedale Civile – PS –
US – New York Med Urgenza Xiamen University No1 Hospital
Mount Sinai Hospital
New York Europe - Italy – Europe - Italy - – Asia - Indonesia –Jakarta
Vienna
Roma Cipto Mangankusumo
Policlinico Gemelli Medical University Hospital Oceania - Australia –
Brisbane
- TIP
US – Maine Europe - Belgium – Prince Charles Hospital
Maine General Hospital Italy – Monza Genk
Ospedale San Ziekenhuis Oost-
US – Jackson Gerardo - TIN
University of Miami Limburg Hospital Asia - Singapore – Oceania - Australia-
Sydney
Europe - Lithuania – - KK Women’s and
Vilnius S Africa Capetown Children’s St George Hospital
UCT University of Capetown
Santariskiu University
South America - Brazil Europe - Netherlands
– Sao Paulo – Maastericht S Africa – Durban Oceania - Australia – Adleaide
Instituta da Crianca, Maastricht University Ethekwinin Hospital and Heart Lyell McEwin Hospital
University Sao Paulo Hospital Centre
----- End of picture text -----

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Chinese Domestic Manufacture - BMPA

Chinese regulatory approval for Uscom and Foxconn

==> picture [169 x 161] intentionally omitted <==

==> picture [246 x 160] intentionally omitted <==

==> picture [286 x 154] intentionally omitted <==

==> picture [193 x 154] intentionally omitted <==

Uscom’s new manufacturing facility in partnership with Foxconn with the first trial devices due for assembly and local sale following recent approval

==> picture [113 x 113] intentionally omitted <==

Beijing Medical Products Authority

• BMPA - Beijing branch of NMPA

• Oversees efficacy, safety and sale of medical devices

• Approval is NMPA equivalent and allows Uscom to sell medical devices throughout China and tender into China’s massive public health system

• • Completion of a 3 year process of testing and documentation

Manufacturing, distribution and investment

• New focus on sophisticated medical technology

• Uscom has >40 IP cases in China and >160 worldwide

• Foundation of new products

• Cost-effective manufacture and reliable supply chain

Foxconn partnership

• Instant manufacturing scale for Uscom.

• High medical technology partner for Foxconn.

• Uscom manufacturing and R&D centre

• Expansion of Foxconn Technology Industry Zone in Beijing

==> picture [264 x 32] intentionally omitted <==

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

FY23 Achievements

==> picture [77 x 44] intentionally omitted <==

==> picture [35 x 34] intentionally omitted <==

US Regulatory

US

FDA approval to sell SpiroSonic AIR digital ultrasonic spirometers in the US market was received. Multiple devices and Apps including the SpiroSonic AIR are now approved for sale into the US market

Uscom Europe Restructured

==> picture [31 x 27] intentionally omitted <==

Europe

Europe New Sales and Marketing appointments Budapest operations restructured New French and Spanish distribution H2 cash flow positive with strong sales pipeline Migration of manufacturing as CY24 forecasts >current capacity

==> picture [257 x 31] intentionally omitted <==

==> picture [26 x 27] intentionally omitted <==

China

Manufacturing and R&D Partnership

Singapore Regional HQ

==> picture [34 x 34] intentionally omitted <==

Regional HQ activities expanded Capital opportunities under evaluation Emerging commercial centre of Asia Geopolitical neutrality and investment stability Expansion of USCOM SNG PTE. LTD. critical next step

Singapore

==> picture [35 x 34] intentionally omitted <==

koneksa

US

eHealth Products

Partnership of Uscom with Koneksahealth for development of premium quality Spirometry hardware and software. NY Based Koneksahealth is digital biomarker health monitoring leader specializing in pharma efficacy trials. This Uscom SpiroSonic platform will soon be available for application with a number of large Koneksa pharma studies specialized in cardiovascular and pulmonary diseases and therapies.

==> picture [26 x 27] intentionally omitted <==

==> picture [32 x 7] intentionally omitted <==

----- Start of picture text -----

Australia
----- End of picture text -----

World’s largest precision electronics manufacturer Manufacturing, distribution and capital mandate Instant scale, reliable supply chain for Uscom Regulatory and distribution connections Manufacturing and R&D facilities USCOM 1A and 3 other devices for development registration and manufacture

Capital Initiatives – In House

Small Parcels Purchase – Resale of small shareholder packages EABB - $620k to buy back UCM shares at offer Discussions with investors re next steps Strategic plan for growth focus in Asia

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au FY21 Results

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Uscom Markets

Milestones

FY23 Capital Initiatives

Addressing Market Value

A difficult year for markets

Illiquidity combined with international downward pressures Global investor uncertainty – inflation and interest rates Uscom Board responded to strengthen the register Positioning the entity for strategic expansion

a. Small parcels sale (SPP) –

Small parcels shareholding of <$500

Small shareholders were offered market price ex brokerage.

66% of small shareholders participated,

66 shareholders sold 1,138,605 shares at $0.045.

13 Month UCM Share trend

==> picture [386 x 212] intentionally omitted <==

----- Start of picture text -----

0.12
0.11
0.1 -51%
0.09
0.08 Max
0.07 Close
Min
0.06
Linear (Close)
0.05
0.04
0.03
$ AUD
Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23
----- End of picture text -----

This left UCM with ~600 registered shareholders.

b. Equal Access Buy Back (EABB) –

59 shareholders sold 11,266,885 shares to Uscom at $0.055 Cost to the company $619,678.00.

The shares were taken off the market,

Total shares reduced from 198,635,884 to 187,368,999 (-5.7%) ~540 remaining shareholders Cash on hand $2.18m following the buy-back.

Both initiatives were conducted in-house

Shares on Issue

UCM Shareholders

==> picture [526 x 168] intentionally omitted <==

----- Start of picture text -----

800 205
700 -23% -6%
700 200
600 200 199
600 540
500
195
400
190
300 187
200
185
100
0 180
FY22 SPP EABB FY22 SPP EABB
million
----- End of picture text -----

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Revenue Growth

==> picture [315 x 139] intentionally omitted <==

==> picture [316 x 139] intentionally omitted <==

==> picture [331 x 139] intentionally omitted <==

Products: USCOM 1A

New Products:

• USCOM Maternal

• USCOM v1

• • USCOM v2 • USCOM v3 • USCOM v4 • ...

Software/Consumables:

• CardioCare

• Consumable 1

• • Consumable 2 • Consumable 3 • Consumable 4 • …

Products: BP+ & BP+ Reporter

New Products:

• BP+

• • BP+ v2 • BP+ v3 • ...

==> picture [128 x 87] intentionally omitted <==

Software/Consumables:

• BP+ Reporter

• • Disposable - 10 • BP+ 2 • …

==> picture [104 x 79] intentionally omitted <==

Products: SpiroSonic FLO, SMART, MOBILE, SpiroReporter

New Products:

• SpiroSonic AIR

• SpiroSonic PRO

• • SpiroSonic v2 • ...

Software/Consumables:

• SpiroReporter v2

• • SpiroFilter

• Disinfectant

• • SpiroSonic APP – SA1 and SA2 • VentiTest - S

• …

==> picture [140 x 140] intentionally omitted <==

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

FY24 Regional Growth Strategy

Uscom SE Asia

==> picture [266 x 267] intentionally omitted <==

Singapore HQ operational hub linking SE Asia, China and Australia

Logistical HQ for distribution and strategic global access

Expanding regional distribution and sales ASEAN 4.8% GDP growth and expected to be the 4[th] biggest world economy by 2030

Uscom Europe

Transform to regional sales and marketing HQ Grow distribution and sales for USCOM 1A, BP+ and SpiroSonic

New operations and partners Expand academic partnerships

==> picture [35 x 35] intentionally omitted <==

==> picture [35 x 35] intentionally omitted <==

==> picture [35 x 36] intentionally omitted <==

==> picture [27 x 27] intentionally omitted <==

==> picture [26 x 27] intentionally omitted <==

==> picture [26 x 27] intentionally omitted <==

Australia Singapore China Hungary UK US

Uscom China

Initiate domestic manufacture with Foxconn Re-ignite domestic sales teams and expand network Prepare BP+ and SpiroSonic for manufacture, marketing and distribution

Develop new products for manufacture with Foxconn

Uscom US

Activate new distribution model to meet post pandemic demand

Prepare for SpiroSonic and BP+ FDA Develop eHealth strategic partnerships

Uscom – Global Growth

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Looking forward

“Vision, technology, culture, and a unique global opportunity”

A rare combination of international tailwinds behind an established and de-risked MedTech enterprise offers astute investors growth opportunities for FY24.

FY23 - A tale of 2 halves

• H2 record sales and revenue, while H1 was challenging

• • Uscom invested in expansion in preparation for rebounding international markets

• FDA (US) and BMPA (China) approvals underwriting future performance

• H2 sales and growing product pipelines validate investment strategy

FY 24 - Drivers from a strong growth platform:

• The operational optimization of Europe – Organic profitability

• Restoration of normal operations in China – Rebound in sales

• The approval of new products worldwide – More products = more revenue

• Stabilising global markets – New growth

• Potential M&A – Incremental growth

Uscom heading into the future

Uscom Overview

FY24 Outlook

Chair's Update

FY23 Results

Milestones

Uscom Markets

Uscom Ltd I FY2023 Annual General Meeting I uscom.com.au

Summary

“ A rare combination of international tailwinds behind an established and de-risked MedTech enterprise offers growth opportunities for FY24 and the future ”

Uscom has invested in the future with IP and products and expanded global operations. Looking to cloud based big data and IO analytics and predictive learning algorithms to enhance the power of our world leading sensors. Global operations and partnerships to increase reach and capital connection to set the foundations for a strategic shift in global efficiencies and reach taking Uscom from an outstanding product developer to a profitable global enterprise of international impact.

==> picture [135 x 61] intentionally omitted <==

==> picture [418 x 284] intentionally omitted <==

Uscom - The Measure of Life

Corporate Responsibility

==> picture [78 x 93] intentionally omitted <==

==> picture [195 x 60] intentionally omitted <==

==> picture [140 x 35] intentionally omitted <==

Questions and Comments ASX: UCM

Prof. Rob Phillips Chairman and CEO, Uscom Limited

Oct 26, 2023

==> picture [140 x 35] intentionally omitted <==

Thank You ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited

Oct 26, 2023